Mirum Pharmaceuticals Stock News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present LIVMARLI (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz bought 7,000 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, November 24th. The stock was acquired at an average price of $14.40 per share, for a total transaction of $100,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is […]

Mirum Pharmaceuticals Inc (MIRM) shares closed 2.5% lower than its previous 52 week low, giving the company a market cap of $410M. The stock is currently down 23.2% year-to-date, down 39.7% over the past 12 months, and up 1.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 52.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -26.4% The company's stock price performance over the past 12 months lags the peer average by 45.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) to announce earnings per share (EPS) of ($0.06) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Mirum Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.66 and the lowest estimate coming in at ($2.36). Mirum Pharmaceuticals posted earnings […]

Mirum Pharmaceuticals Inc (MIRM) shares closed 0.1% lower than its previous 52 week low, giving the company a market cap of $438M. The stock is currently down 18.0% year-to-date, down 34.1% over the past 12 months, and up 8.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 32.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -41.2% The company's stock price performance over the past 12 months lags the peer average by 41.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities research analysts forecast that Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) will announce sales of $70.71 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Mirum Pharmaceuticals earnings, with the highest sales estimate coming in at $145.90 million and the lowest estimate coming in at $3.23 million. The company is expected []

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been assigned an average rating of Buy from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. []

Mirum Pharmaceuticals (NASDAQ:MIRM) announced its quarterly earnings results on Monday. The company reported ($1.55) earnings per share for the quarter, topping analysts consensus estimates of ($1.63) by $0.08, MarketWatch Earnings reports. During the same period last year, the company posted ($0.86) EPS. Shares of MIRM stock traded up $0.38 during trading on Tuesday, hitting $15.87. []

Mirum Pharmaceuticals (NASDAQ:MIRM) released its quarterly earnings results on Monday. The company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.08, MarketWatch Earnings reports. During the same quarter in the previous year, the company earned ($0.86) earnings per share. MIRM traded up $0.49 during trading hours on […]